The Danish drugmaker is presenting investors with a puzzle: its own treasury desk is hoovering up shares at a record clip, while at least one major bank is telling clients to head for the exits. The tension between those two messages captures the current state of Novo Nordisk far better than any single price target.
Deutsche Bank cut its rating on the stock from “Hold” to “Sell” yesterday, trimming the price objective from 290 to 265 Danish kroner. The move follows the failure of the cardiovascular candidate Ziltivekimab in a Phase-3 trial, compounded by intensifying competitive pressure from Eli Lilly across the GLP-1 franchise. For a company whose valuation rests so heavily on future growth, a pipeline setback of this magnitude carries outsized weight.
Yet the company’s own capital allocation strategy tells a different story. Between August 17 and 21, Novo Nordisk repurchased 1,045,000 B-shares for 309.2 million Danish kroner, following a purchase of one million shares the prior week at an average price of 303.04 kroner. The broader buyback program, authorized at 15 billion kroner, continues without interruption, with the treasury now holding nearly 44 million B-shares—roughly one percent of share capital. Add to that a dividend of $0.5786 per share paid on August 25 to shareholders of record as of August 17, and the picture emerging from the company’s own actions is one of conviction, not caution.
A Regulatory Race With Stakes Beyond the Needle
The operational front offers a more mixed landscape. China’s drug regulator has formally accepted Novo Nordisk’s marketing application for the oral formulation of Wegovy, opening a path into the world’s largest obesity market. No decision timeline has been set, but acceptance alone represents a meaningful foothold. The European Commission, meanwhile, granted approval on July 15 for the once-daily oral version of Wegovy for weight management in adults with obesity or overweight accompanied by at least one weight-related comorbidity.
The complication is that Lilly is already moving faster. Its oral GLP-1 therapy Foundayo launched in the UK this week—the first European market for the product—while Novo Nordisk still navigates the approval process for its own pill in that region. The pattern is becoming familiar: each regulatory advance from Novo is quickly matched or surpassed by a Lilly market entry. The US Food and Drug Administration, for instance, recently cleared Lilly’s Mounjaro for cardiovascular risk reduction, an indication Novo Nordisk also has in its sights.
There is nuance beneath the surface, however. Novo Nordisk initiated its Phase-3 OASIS-5 study on August 12, a trial running through 2028 that aims to identify the lowest effective maintenance dose of the Wegovy pill. That seemingly mundane detail could ultimately determine tolerability, manufacturing costs, and market share. The company is also working with its Novonesis subsidiary on microbiome-based adjuncts to GLP-1 therapies, with data expected in the second half of 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Reimbursement Cloud Hanging Over the Sector
The most significant threat may not be Lilly at all. Reports this week indicate US employers are increasingly planning to drop GLP-1 coverage from health plans in 2027 as costs spiral. That would strike at the heart of Novo Nordisk’s most profitable market, where obesity and diabetes treatments have generated substantial revenue. A promising pipeline matters little if the payers retreat.
Adding to the friction, Scholar Rock withdrew its European application for a spinal muscular atrophy treatment following issues at a Novo Nordisk production facility in Bloomington, Indiana. The episode underscores how deeply the company has become embedded as a contract manufacturer for other pharmaceutical firms—and how vulnerable that web can be.
Where the Stock Actually Stands
The share price has absorbed these crosscurrents with notable composure. After yesterday’s 2.2 percent decline, the stock sits at €39.67, roughly 28 percent below its 52-week high of €54.86 reached in January. The gap to the 200-day moving average of €40.21 is a mere 1.4 percent—hardly the profile of a free-falling equity. Since the start of the year, the shares have lost about ten percent, with an 18 percent decline over twelve months.
J.P. Morgan offers a more measured perspective. On August 25, the bank reaffirmed its neutral stance while raising its price target from 250 to 275 kroner, citing improved growth prospects for Ozempic and Wegovy outside the United States. That is neither euphoria nor alarm—just a recognition that the international opportunity remains intact even as domestic headwinds build.
The real test arrives on September 21, when Novo Nordisk hosts its capital markets day and is expected to detail its next-generation obesity and diabetes pipeline. Until then, the stock sits in an unusual position: analysts and fundamentals pointing in different directions, with the company’s own buyback program as the clearest signal of internal sentiment. Investors will have to decide which message carries more weight.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 28 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 28.
Novo Nordisk: Buy or sell? Read more here...
